Eli Lilly and Co  

(Public, NYSE:LLY)   Watch this stock  
Find more results for LLY
84.54
0.00 (0.00%)
Jul 31 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 84.38 - 85.25
52 week 60.14 - 90.18
Open 84.88
Vol / Avg. 4.11M/5.70M
Mkt cap 93.68B
P/E 43.88
Div/yield 0.50/2.37
EPS 1.93
Shares 1.11B
Beta 0.30
Inst. own 77%
Oct 22, 2015
Q3 2015 Eli Lilly and Co Earnings Release - 9:30AM EDT - Add to calendar
Oct 22, 2015
Q3 2015 Eli Lilly and Co Earnings Call - 9:00AM EDT - Add to calendar
Jul 23, 2015
Q2 2015 Eli Lilly and Co Earnings Release
Jul 23, 2015
Q2 2015 Eli Lilly and Co Earnings Call
Jun 23, 2015
Eli Lilly and Co Webcast to Discuss Ixekizumab Phase III Data
Jun 11, 2015
Lilly and Incyte Webcast to Discuss Baricitinib Phase III Data
Jun 9, 2015
Eli Lilly and Co at Goldman Sachs Healthcare Conference
Jun 7, 2015
Eli Lilly and Co Diabetes Business Update
May 13, 2015
Eli Lilly and Co at Bank of America Merrill Lynch Health Care Conference
May 4, 2015
Eli Lilly and Co Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 12.07% 12.19%
Operating margin 12.78% 13.56%
EBITD margin - 24.00%
Return on average assets 6.72% 6.60%
Return on average equity 16.29% 14.49%
Employees 39,135 -
CDP Score - 85 B

Address

Lilly Corporate Ctr
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company's products are sold in approximately 120 countries. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Officers and directors

John C. Lechleiter Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Derica W. Rice Chief Financial Officer, Executive Vice President - Global Services
Age: 50
Bio & Compensation  - Reuters
Maria A. Crowe President - Manufacturing Operations
Age: 55
Bio & Compensation  - Reuters
Jan M. Lundberg Ph.D. Executive Vice President - Science and Technology, President - Lilly Research Laboratories
Age: 61
Bio & Compensation  - Reuters
Melissa S. Barnes Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
Age: 46
Bio & Compensation  - Reuters
Michael J. Harrington Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Stephen F. Fry Senior Vice President - Human Resources and Diversity
Age: 49
Bio & Compensation  - Reuters
Darren J. Carroll Senior Vice President - Corporate Business Development
Bio & Compensation  - Reuters
Enrique A. Conterno Senior Vice President and President - Lilly Diabetes
Age: 48
Bio & Compensation  - Reuters
Susan Mahony Ph.D. Senior Vice President and President - Lilly Oncology
Age: 50
Bio & Compensation  - Reuters